Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E53.87 EPS (ttm)6.87 Insider Own0.50% Shs Outstand106.28M Perf Week-5.27%
Market Cap39.30B Forward P/E25.89 EPS next Y14.29 Insider Trans-1.16% Shs Float77.64M Perf Month10.06%
Income797.40M PEG2.83 EPS next Q3.13 Inst Own70.70% Short Float4.95% Perf Quarter-7.15%
Sales4.73B P/S8.31 EPS this Y85.10% Inst Trans0.24% Short Ratio4.53 Perf Half Y-6.25%
Book/sh42.84 P/B8.63 EPS next Y21.79% ROA13.00% Target Price450.71 Perf Year-33.80%
Cash/sh13.25 P/C27.91 EPS next 5Y19.05% ROE20.00% 52W Range325.35 - 563.79 Perf YTD-31.88%
Dividend- P/FCF46.90 EPS past 5Y44.90% ROI16.00% 52W High-34.86% Beta1.83
Dividend %- Quick Ratio3.40 Sales past 5Y55.00% Gross Margin92.90% 52W Low12.88% ATR13.40
Employees4300 Current Ratio3.60 Sales Q/Q7.30% Oper. Margin25.60% RSI (14)39.12 Volatility2.27% 3.84%
OptionableYes Debt/Eq0.09 EPS Q/Q25.30% Profit Margin16.90% Rel Volume0.68 Prev Close369.82
ShortableYes LT Debt/Eq0.09 EarningsNov 04 BMO Payout0.00% Avg Volume849.78K Price367.26
Recom2.40 SMA20-7.83% SMA50-4.67% SMA200-5.61% Volume287,884 Change-0.69%
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Dec-06-16 10:14AM  Play the Trump Factor with these 4 Large-Cap Stocks
Dec-05-16 03:48PM  Here's Why Regeneron Pharmaceuticals, Inc. Jumped 9.4% in November at Motley Fool
Dec-02-16 07:00PM  Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age
04:05PM  Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
03:02PM  Regeneron's CEO Blasts Peers on Innovation at Motley Fool
02:42PM  The Numbers Behind a Pharma CEO Shouting Match at Bloomberg
Dec-01-16 09:53PM  Pharma CEOs got into a heated debate over why people hate the industry
06:33PM  Pharma execs weigh in on possible changes under Trump Reuters
04:52PM  Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC
04:48PM  What Regeneron's CEO Thinks About Drug Pricing Under Trump
04:20PM  5 Top Performing Biotechnology Stocks of November
01:56PM  Drugs Delayed By Regeneron, Sanofi Plant (REGN, SNY) at Investopedia
01:45PM  Regeneron CEO on drug pricing
11:20AM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 1, 2016
Nov-30-16 12:57PM  Sanofi SA (ADR) (SNY) Facing Manufacturing Headache On Two Blockbusters at Insider Monkey
09:30AM  NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
07:37AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : November 30, 2016
Nov-29-16 09:28AM  Celgene vs. Regeneron: Which Stock is a Better Pick?
08:15AM  Blog Coverage Recro Pharma Shares Soared Nearly 20% after Reporting Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam Accesswire
Nov-28-16 10:05AM  Gilead Sciencess HCV Fall Was Partially Offset by HIV Business
Nov-25-16 09:00AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Nov-23-16 03:14PM  3 Biotechs That Don't Pay Dividends -- but Could at Motley Fool
06:31AM  Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola
Nov-22-16 10:04AM  The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
06:02AM  Attention, Biotech Investors: Black Friday Is Already Here at Motley Fool
Nov-21-16 12:20PM  Regeneron Sarilumab Drug Tops Humira (REGN, SNY) at Investopedia
08:30AM  Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year PR Newswire
08:12AM  Vetr Thinks Regeneron Is Looking Healthy
Nov-18-16 05:27PM  Aegerion's Juxtapid Gets Pricing Authorization in Japan
03:52PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
10:24AM  Gilead Sciences: Buy 'Regeneron Lite'Or Just Buy Regeneron? at
08:02AM  Regeneron/Sanofi's Praluent CV Outcomes Study to Continue
06:18AM  Sanofi/Regeneron Present Sarilumab Data at ACR Meeting
06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Nov-17-16 10:04AM  Why Regeneron is Tumbling at
04:50AM  No early win for Sanofi, Regeneron cholesterol drug in study
02:02AM  Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis GlobeNewswire
02:00AM  Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis PR Newswire
Nov-16-16 04:29PM  Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster
08:02AM  Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting GlobeNewswire
08:00AM  Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
Nov-15-16 04:18PM  Soros 13F Points to More Than Just Emerging Markets at Investopedia
11:45AM  Amgen cholesterol drug reduces artery-clogging plaque in study
11:45AM  Amgens Repatha Unclogs Arteries in Good Sign for Future Sales at Bloomberg
09:10AM  Teva Shares Lower on Third Quarter Results
07:07AM  Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies GlobeNewswire
07:00AM  Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies GlobeNewswire
Nov-14-16 04:02PM  Supernus, Puma Among 5 Biotech Stock Winners, Losers Monday +5.89%
06:14AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-13-16 11:20AM  Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
Nov-11-16 09:35AM  Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep at 24/7 Wall St.
09:00AM  Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016 PR Newswire
07:18AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : November 11, 2016
08:31AM  Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now
Nov-09-16 02:04PM  What Do Analysts Say about Regeneron after 3Q16 Earnings? +13.77%
01:04PM  What Drove Regenerons 3Q16 Performance?
10:48AM  How Did Regeneron Perform in 3Q16?
06:38AM  Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed
Nov-08-16 05:30PM  Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October -- Here's Why at Motley Fool
12:35PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : November 8, 2016
Nov-07-16 04:29PM  Which Four Biotechs Are Derisked, Buyable Ahead of Election Day? +7.03%
12:22PM  Top Research Reports for Exxon, Duke & Gilead
09:10AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
12:07AM  Business Watch at The Wall Street Journal
Nov-05-16 06:35AM  Regeneron 3Q Net $265M, or $2.27 a Share (REGN) at Investopedia
Nov-04-16 05:40PM  SPY ETF Tests A Key Level As Every S&P Sector Posts A Weekly Loss
05:13PM  Regeneron (REGN) Stock Closed Up on Q3 Results
04:11PM  Regeneron Bounds On EPS Beat; Stock Muzzled On Amgen Drug Brouhaha
03:50PM  Regeneron (REGN) Beats on Q3 Earnings, Misses on Sales
02:51PM  3 Things You Really Need to Know About Regeneron Pharmaceuticals' Q3 Results at Motley Fool
02:00PM  Edited Transcript of REGN earnings conference call or presentation 4-Nov-16 12:30pm GMT
12:43PM  Regeneron profit tops Street on lower costs
11:54AM  Regeneron: 'We Like the Risk Reward' at
10:05AM  Regeneron Investors Cheer Q3 Earnings Beat, Eylea Growth
09:46AM  The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
09:05AM  Regeneron (REGN) Q3 Earnings Top Estimates, Sales Miss
08:35AM  US stock futures hold around breakeven after jobs report misses estimate at CNBC
08:12AM  [$$] Regeneron Revenue Growth Slows at The Wall Street Journal
08:00AM  Early movers: HUM, REGN, ITT, SBUX, CBS, LVS, KHC, LGF, WTW, HLF & more at CNBC
07:34AM  Regeneron's Q3 Results Mixed Compared To Analyst Estimates
07:15AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q3 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:41AM  Regeneron tops 3Q profit forecasts
06:39AM  Eylea sales lift Regeneron revenue 7.3 percent
06:30AM  Regeneron Reports Third Quarter 2016 Financial and Operating Results PR Newswire
Nov-03-16 09:22AM  Drug Stocks to Watch for Earnings on Nov 4; REGN & More
08:49AM  Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay
Nov-02-16 10:05AM  Strensiq: A Potential Driver for Alexion
06:00AM  'Mad Money' Lightning Round: On Biotechs, Wait Until After the Election
Nov-01-16 04:10PM  Pfizer Ends Cholesterol Drug Development, Lowers EPS Guidance
02:57PM  3 Things You Really Need to Know About Pfizer's Q3 Results at Motley Fool
02:23PM  Align, Incyte, GrubHub Among Best R&D Stock Plays: Goldman
12:39PM  Pfizer's Surprising News Upends the Market for Next-Gen Cholesterol Busters at Motley Fool
12:05PM  Pfizer: It's Never Just the Earnings at
11:15AM  FDA approval delayed for Sanofi Genzymes next blockbuster at
09:08AM  Regeneron (REGN) Q3 Earnings: Will the Stock Surprise?
Oct-31-16 06:04PM  Analyst Recommendations for BioMarin after Its 3Q16 Earnings
11:09AM  Analysts Recommendations for Amgen and Its Peers in 2016
09:22AM  [$$] FDA Rejects Sanofi-Regeneron Arthritis Drug Over Plant Deficiencies at The Wall Street Journal
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products; and collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize fasinumab, an investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. The company also has a strategic collaboration, option, and license agreement with Ocular Therapeutix for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other retinal diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM